首页> 外文OA文献 >Discovery of the S1P2 Antagonist GLPG2938 (1-2-Ethoxy-6-(trifluoromethyl)-4-pyridyl-3-5-methyl-6-1-methyl-3-(trifluoromethyl)pyrazol-4-ylpyridazin-3-ylmethylurea) a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

【2h】

Discovery of the S1P2 Antagonist GLPG2938 (1-2-Ethoxy-6-(trifluoromethyl)-4-pyridyl-3-5-methyl-6-1-methyl-3-(trifluoromethyl)pyrazol-4-ylpyridazin-3-ylmethylurea) a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

机译：S1P2拮抗剂GLPG2938的发现（1- 2-乙氧基-6-（三氟甲基）-4-吡啶基 -3 - 5-甲基-6- 1-甲基-3-（三氟甲基）吡唑-4- y1吡啶嗪-3-基甲基尿素）治疗特发性肺纤维化的临床前候选者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 -1
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis [J] . Mammoliti Oscar, Palisse Adeline, Joannesse Caroline, Journal of Medicinal Chemistry . 2021,第9期

机译：S1P2拮抗剂GLPG2938的发现（1- [2-乙氧基-6-（三氟甲基）-4-吡啶基] -3 - [[5-甲基-6- [1-甲基-3-（三氟甲基）吡唑-4- y1 ]吡啶汀-3-基]甲基]尿素），一种治疗特发性肺纤维化的临床前候选者
2. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido(4,3-d)pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. [J] . Kalgutkar AS, Griffith DA, Ryder T, Chemical research in toxicology . 2010,第6期

机译：发现策略可减轻因与2-（2-羟芳基）-5-（三氟甲基）吡啶基（4,3-d）嘧啶-4（3h）-一衍生物，有效的钙敏感受体拮抗剂和治疗骨质疏松症的临床候选药物。
3. The discovery and preclinical characterization of 6-chloro-N-(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl) quinoline-5-carboxamide based P2X7 antagonists [J] . Rech Jason C., Bhattacharya Anindya, Branstetter Bryan J., Bioorganic and Medicinal Chemistry Letters . 2016,第19期

机译：基于P2X7的6-氯-N-（2-（4,4-二氟哌啶-1-基）-2-（2-（三氟甲基）嘧啶-5-基）乙基）喹啉-5-甲酰胺的发现和临床前表征拮抗剂
4. Idiopathic Pulmonary Fibrosis: Pathogenesis, Progression, Treatments, and Future Prospects [D] . Ouchi, Hideyasu. 2019

机译：特发性肺纤维化：发病机制，进展，治疗和未来前景
5. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018 a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis [O] . Zhenhua Huang, Heran Li, Qian Zhang, 2015

机译：KBP-7018的临床前体外和体内药代动力学特性的表征KBP-7018是新型酪氨酸激酶抑制剂候选药物用于治疗特发性肺纤维化
6. Pan-transcriptome-based Candidate Therapeutic Discovery for Idiopathic Pulmonary Fibrosis [O] . Yunguan Wang, Jaswanth K. Yella, Sudhir Ghandikota, 2019

机译：基于转录组的候选性肺纤维化治疗疗法

Discovery of the S1P2 Antagonist GLPG2938 (1-2-Ethoxy-6-(trifluoromethyl)-4-pyridyl-3-5-methyl-6-1-methyl-3-(trifluoromethyl)pyrazol-4-ylpyridazin-3-ylmethylurea) a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

著录项

相似文献

相关主题

期刊订阅